#Newspaper
The Jiang Zemin’s universe and P4 lab: making big pharmaceutical businesses out of the COVID-19 pandemic
(21 Apr) Jiang Zemin’s son is Jiang Mianheng. Chen Zhu is a partner of Jiang Mianheng. Both of them are former Vice Presidents of the China Academy of Science (CAS) and responsible for the design, funding and construction of the P4 Lab. Chen Zhu is now president of the Red Cross Society in China. The current director of the P4 Lab is Yuan Zhiming. Mr. Yuan is a partner with Jiang Zemin’s grandson, Jiang Zhicheng, in Wuxi AppTec. Wuxi AppTec’s subsidiary company: Fosun Pharma has an exclusive partnership with Gilead in listed pharmaceutical businesses in China. Gilead owns the patent rights for Remdesivir to cure COVID-19. However, P4 lab pushed ahead of the registration of patent ‘rights’ for Remdesivir on 21st January, even before Gilead, when the latter meant to ‘give’ CCP a clinical trial of Remdesivir free. In response to this, Gilead announced publicly on 8th Feb that they had ‘no right’ to intervene in how China’s researchers' registration the ‘trademark’ of Remdesivir. They were ‘working hard’ to push feasible production. The cost and price of the drug were not discussed.
Full translation:
https://telegra.ph/The-Jiang-Zemin-Galaxy-and-P4-lab-making-big-pharmaceutical-businesses-out-of-the-COVID-19-pandemic-04-28
Sources: Gateway Pundit, The Sydney Morning Herald, Science Net and Epoch Times
#Pandemic #Redemsivir #WuhanP4lab #Gilead #JiangZemin #JiangMianheng #SunLijun #JiangZhicheng #MengJianzhu
The Jiang Zemin’s universe and P4 lab: making big pharmaceutical businesses out of the COVID-19 pandemic
(21 Apr) Jiang Zemin’s son is Jiang Mianheng. Chen Zhu is a partner of Jiang Mianheng. Both of them are former Vice Presidents of the China Academy of Science (CAS) and responsible for the design, funding and construction of the P4 Lab. Chen Zhu is now president of the Red Cross Society in China. The current director of the P4 Lab is Yuan Zhiming. Mr. Yuan is a partner with Jiang Zemin’s grandson, Jiang Zhicheng, in Wuxi AppTec. Wuxi AppTec’s subsidiary company: Fosun Pharma has an exclusive partnership with Gilead in listed pharmaceutical businesses in China. Gilead owns the patent rights for Remdesivir to cure COVID-19. However, P4 lab pushed ahead of the registration of patent ‘rights’ for Remdesivir on 21st January, even before Gilead, when the latter meant to ‘give’ CCP a clinical trial of Remdesivir free. In response to this, Gilead announced publicly on 8th Feb that they had ‘no right’ to intervene in how China’s researchers' registration the ‘trademark’ of Remdesivir. They were ‘working hard’ to push feasible production. The cost and price of the drug were not discussed.
Full translation:
https://telegra.ph/The-Jiang-Zemin-Galaxy-and-P4-lab-making-big-pharmaceutical-businesses-out-of-the-COVID-19-pandemic-04-28
Sources: Gateway Pundit, The Sydney Morning Herald, Science Net and Epoch Times
#Pandemic #Redemsivir #WuhanP4lab #Gilead #JiangZemin #JiangMianheng #SunLijun #JiangZhicheng #MengJianzhu
Telegraph
The Jiang Zemin's Universe and P4 lab: making big pharmaceutical businesses out of the COVID-19 pandemic
(21 Apr) Jiang Zemin’s son is Jiang Mianheng. Chen Zhu is a partner of Jiang Mianheng. Both of them are former Vice Presidents of the China Academy of Science (CAS) and responsible for the design, funding and construction of the P4 Lab. Chen Zhu is now president…